CRISPR Therapeutics AG Annual Operating Income (Loss) in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CRISPR Therapeutics AG quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2023.
  • CRISPR Therapeutics AG Operating Income (Loss) for the quarter ending June 30, 2024 was -$151M, a 58.8% decline year-over-year.
  • CRISPR Therapeutics AG Operating Income (Loss) for the twelve months ending June 30, 2024 was -$355M, a 25.1% increase year-over-year.
  • CRISPR Therapeutics AG annual Operating Income (Loss) for 2023 was -$223M, a 66.9% increase from 2022.
  • CRISPR Therapeutics AG annual Operating Income (Loss) for 2022 was -$673M, a 280% decline from 2021.
  • CRISPR Therapeutics AG annual Operating Income (Loss) for 2021 was $374M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$223M +$451M +66.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 -$673M -$1.05B -280% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $374M +$728M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$354M -$401M -858% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $46.7M +$206M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$159M -$94.3M -146% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$64.6M +$3.48M +5.11% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 -$68.1M -$42.4M -165% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 -$25.7M -$19.1M -288% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$6.63M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.